Acadian Asset Management
ABUS icon

Acadian Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Acadian Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-119,020
Closed -$361K – 1687
2021
Q2 		$361K Buy
119,020
+83,717
+237% +$259K ﹤0.01% 1260
2021
Q1 		$118K Buy
+35,303
New +$136K ﹤0.01% 1635
2014
Q3 		– Sell
-5,799
Closed -$76K – 1045
2014
Q2 		$76K Sell
5,799
-72,725
-93% -$1.03M ﹤0.01% 887
2014
Q1 		$1.71M Buy
78,524
+5,800
+8% +$104K 0.01% 506
2013
Q4 		$579K Buy
+72,724
New +$606K ﹤0.01% 658

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acadian Asset Management's ABUS Position: Q3 2021 in Review

Acadian Asset Management sold out of Arbutus Biopharma (ABUS) in Q3 2021, closing a stake of 119,020 shares — an estimated $361K sold.

Acadian Asset Management first reported a position in ABUS in Q4 2013 and held it in 5 quarters. The position peaked at $1.71M in Q1 2014. 99 funds tracked by Wall St. Rank hold ABUS as of Q3 2021.

  • Acadian Asset Management reported no remaining Arbutus Biopharma position as of Q3 2021 after selling out during the quarter.
  • Acadian Asset Management sold 119,020 Arbutus Biopharma shares in Q3 2021, an estimated $361K.
  • Acadian Asset Management first reported a position in Arbutus Biopharma in Q4 2013 and held it in 5 quarters.
  • Acadian Asset Management's Arbutus Biopharma position peaked at $1.71M in Q1 2014.
  • 99 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2021.

Based on Acadian Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.